Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, Valentina Guarneri, Aleix Prat

Research output: Contribution to journalReview article

Abstract

Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g. HER2-enriched disease) are more immunogenic than others (e.g. Luminal A or B). From a clinical perspective, the immune system plays a relevant prognostic role in HER2+ breast cancer and contributes to the therapeutic effects of trastuzumab. However, as more HER2-targeted agents become available, a better understanding of the role played by the immune system in modulating therapy response to different agents will be needed. Furthermore, the recent introduction in oncology of immune checkpoint inhibitors capable of unleashing anti-tumor immune response opens new possibilities for therapeutic combinations in HER2+ breast cancer. Here, we review the current pre-clinical and clinical data on the interplay between the immune system and HER2+ breast cancer, focusing on different HER2-targeted treatments and the biological heterogeneity that exists within HER2+ disease. Finally, we discuss new therapeutic approaches exploiting the immune system to increase activity or revert resistance to HER2-targeted agents.

Original languageEnglish
Article number90
Pages (from-to)1-14
Number of pages14
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue number1
DOIs
Publication statusPublished - Mar 29 2019

Fingerprint Dive into the research topics of 'Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer'. Together they form a unique fingerprint.

  • Cite this